10-Q: PMGC Holdings Q3 2025: Diversification Drives Revenue Growth

PMGC Holdings Inc. reports significant revenue growth in Q3 2025 driven by recent acquisitions in IT packaging and precision engineering, despite an increased net loss and ongoing going concern doubts.

Summary

• PMGC Holdings Inc. has transitioned from a skincare development company to a diversified holding company, completing the sale of its skincare business on January 16, 2025.
• The company acquired Pacific Sun Packaging Inc. (custom IT packaging) on July 7, 2025, and AGA Precision Systems LLC (CNC machining) on July 18, 2025, as part of its diversification strategy.
• Revenue from continuing operations for the nine months ended September 30, 2025, was $285,948, a significant increase from $0 in the prior year, primarily due to the new acquisitions.
• The net loss from continuing operations for the nine months ended September 30, 2025, increased to $(4,776,319) compared to $(2,298,885) for the same period in 2024.
• Total net loss for the nine months ended September 30, 2025, was $(4,765,130), up from $(4,310,998) in the prior year.
• The company's cash balance increased to $7,700,562 as of September 30, 2025, from $3,984,453 at December 31, 2024, largely due to financing activities.
• Working capital improved slightly to $4,310,939 as of September 30, 2025, from $4,251,867 at December 31, 2024.
• An accumulated deficit of $18,034,757 as of September 30, 2025, and continued operating losses raise substantial doubt about the company's ability to continue as a going concern.
• The company completed multiple reverse stock splits, resulting in a combined 1-for-4,900 reverse split, retrospectively adjusted in all comparative figures.
• PMGC entered into an Equity Line of Credit (ELOC) for up to $20,000,000 and consummated a first pre-paid purchase of $5,000,000 in convertible debt.

Sentiment

Score: 3

Explanation: While the company has made strategic moves to diversify and generate new revenue, the significant increase in net loss, the explicit 'going concern' warning, and the heavy reliance on continuous capital raises indicate severe financial instability and high risk. The strategic shift offers potential, but current financial health is poor.

Positives

• Successfully diversified its business model by divesting the skincare segment and acquiring two new operating companies, Pacific Sun Packaging Inc. and AGA Precision Systems LLC.
• Generated $285,948 in revenue from continuing operations for the nine months ended September 30, 2025, compared to $0 in the prior year, demonstrating initial success in the new business segments.
• Increased cash on hand to $7,700,562 as of September 30, 2025, primarily through successful financing activities.
• Northstrive BioSciences Inc. is actively developing its lead asset, EL-22, a biopharmaceutical product leveraging an engineered probiotic approach for obesity, including GLP-1 receptor agonists.
• Achieved a gross margin of 27% for the nine months ended September 30, 2025, with the IT packaging segment showing a normalized gross margin of 45% after fair value adjustments.
• Recognized a gain of $129,613 on the termination of an intangible asset (License #1), improving other income.
• Improved other income (expense) for the three months ended September 30, 2025, with a net loss of $(417,117) compared to $(576,238) in the same period of 2024, driven by decreased interest expense and finance costs.

Negatives

• Reported a significant increase in net loss from continuing operations to $(4,776,319) for the nine months ended September 30, 2025, from $(2,298,885) in the prior year.
• The company has an accumulated deficit of $18,034,757 and continues to incur net losses and use cash in operating activities, raising substantial doubt about its ability to continue as a going concern.
• Operating expenses increased substantially, with consulting fees up by $582,585, office and administrative expenses up by $807,539, and professional fees up by $673,321 for the nine months ended September 30, 2025.
• Incurred a realized loss on investments of $397,365 for the nine months ended September 30, 2025.
• The company has undergone multiple reverse stock splits (1-for-200, 1-for-7, and 1-for-3.5, totaling 1-for-4,900), which can be a negative indicator for investor confidence.
• High customer concentration, with 5 key customers representing approximately 75% of revenue and the largest customer accounting for 23% of revenue for the nine months ended September 30, 2025.
• High supplier concentration, with 2 key suppliers representing approximately 28% of the cost incurred in inventory purchase and production for the nine months ended September 30, 2025.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to accumulated deficit and ongoing operating losses.
• Reliance on raising additional debt or equity financing to fund operations and execute business plans.
• Challenges in integrating newly acquired businesses and generating anticipated cash flows from these assets.
• Exposure to general economic and business conditions, including changes in interest rates.
• Sensitivity to prices of competitive products and costs associated with research and development.
• Potential impact of disease outbreaks, political unrest, natural disasters, terrorist acts, acts of war, and military operations on business.
• Risks related to data security breaches, failure of information security systems, and cyber-attacks.
• Vulnerability to actions by government authorities, including changes in government regulation.
• Uncertainties associated with ongoing legal proceedings and potential future litigation.
• Fluctuations in the size of the medical aesthetics, cosmetics, and biotechnology market.
• Risk of misjudgments in preparing forward-looking statements and executing prospective business plans.
• Inability to keep pace with advances in medical aesthetics and biotechnology.
• Challenges in designing, developing, marketing, and selling new medical aesthetics and biotech products to generate revenue and positive cash flows.
• Dependency on certain key personnel and the ability to retain and attract qualified personnel.
• Risks related to obtaining, maintaining, protecting, defending, and enforcing intellectual property rights.
• Potential disruption of supply or shortage of raw materials for manufacturing operations.
• Unavailability, reduction, or elimination of government and economic incentives.
• Failure to manage future growth effectively across a diversified portfolio.
• Exposure to inflation risk, particularly increases in labor costs, which could impair operating results.

Future Outlook

Management intends to focus on increasing revenue through its multi-strategy investment vehicle, PMGC Capital LLC, by acquiring and managing undervalued assets, public and private investments, and structured financing opportunities. The company plans to establish new wholly-owned subsidiaries to develop and commercialize newly acquired or licensed assets across various industries. Clinical validation studies will be utilized to strengthen the commercial potential and scientific credibility of portfolio companies' technologies, with a specific focus on advancing NorthStrive Biosciences, Inc.'s EL-22 toward Investigational New Drug (IND) applications. PMGC also plans to pursue additional acquisitions of operating business-to-business companies with positive EBITDA and evaluate potential opportunities such as out-licensing biotechnology applications, spin-offs, and creating new publicly traded companies like SPACs. The company expects an improvement in liquidity and capital resources, including cash from the sale of investment securities and potential earn-out payments from the skincare business disposition.

Management Comments

• "We believe we have sufficient funds to continue current operations for at least the next 12 months from the issuance date of the unaudited condensed consolidated financial statements."
• "We may seek to raise additional capital to accelerate the execution of management's plans."
• "The Company continually evaluates the performance of its suppliers and the availability of alternatives to substitute or supplement its inventory production supply chain. The Company believes that a breakdown in supply from one of its key suppliers would be overcome in a short amount of time given the availability of alternatives."
• "The Company is in the process of evaluating the purchase price allocation and determining the fair value of identifiable assets acquired and liabilities assumed, which will be reflected in subsequent reporting periods in accordance with ASC 805, Business Combinations." (Regarding the Indarg Engineering acquisition)

Industry Context

PMGC Holdings Inc.'s strategic pivot from a specialized skincare company to a diversified holding company reflects a broader trend among smaller entities to mitigate single-industry risks and capitalize on opportunities across multiple sectors. The entry into biopharmaceuticals with Northstrive BioSciences, particularly targeting obesity with EL-22, positions the company in a high-growth market driven by increasing demand for weight loss solutions, including GLP-1 receptor agonists. Simultaneously, the acquisitions in IT packaging (Pacific Sun Packaging Inc.) and precision engineering/CNC machining (AGA Precision Systems LLC) indicate a move towards industrial and technology-driven B2B segments, likely seeking more stable, diversified revenue streams. The multi-strategy investment approach through PMGC Capital LLC is a common model for holding companies aiming for inorganic growth and asset management, but it also introduces complexity and requires robust due diligence and integration capabilities.

Comparison to Industry Standards

• The company's explicit 'going concern' warning and substantial accumulated deficit of over $18 million place its financial health significantly below industry standards for stable, profitable operating companies.
• The gross margin of 27% for the nine months ended September 30, 2025, is a new metric for the diversified entity. While the IT packaging segment's normalized gross margin of 45% (after fair value adjustments) appears competitive, the overall blended margin needs to be assessed against specific benchmarks for IT packaging and precision engineering sectors.
• The high customer concentration (75% of revenue from 5 key customers) and supplier concentration (28% of costs from 2 key suppliers) in the new segments introduce higher operational and revenue risk compared to more diversified industry peers.
• The multiple reverse stock splits (a combined 1-for-4,900) are generally viewed negatively by the market, often indicating a struggle to maintain share price and meet listing requirements, contrasting sharply with the performance of healthy, growing companies.
• The pursuit of Investigational New Drug (IND) applications for biopharmaceutical assets like EL-22 is standard for the biotech industry, but the high failure rate and extensive capital requirements for drug development mean this segment carries significant inherent risk, typical for early-stage biotech but a substantial undertaking for a newly diversified holding company.

Management Changes

Corporate Governance

Legal Proceedings

• Settled an ongoing dispute in February 2025 to avoid litigation costs and burdens, with terms remaining confidential and no admission of liability or fault.
• An ongoing dispute existed as of September 30, 2025, with mediation discussions in progress; the likelihood of an unfavorable outcome or the amount of potential loss is not yet predictable.

Related Party Transactions

• Incurred consulting fees and contracted performance bonuses of $504,900 to GB Capital Ltd., a company controlled by Graydon Bensler (CEO, CFO, and Director), for the nine months ended September 30, 2025.
• Incurred consulting fees and contracted performance bonuses of $555,000 to Northstrive Companies Inc., a company controlled by Braeden Lichti (Non-executive Chairman), for the nine months ended September 30, 2025.
• Incurred directors fees of $41,625 to George Kovalyov (Director) for the nine months ended September 30, 2025.
• Incurred directors fees of $41,680 to Juliana Daley (Director) for the nine months ended September 30, 2025.
• Incurred directors fees of $41,625 to Mystic Marine Advisors, LLC, a company owned and controlled by Jeffrey Parry (Director), for the nine months ended September 30, 2025.
• Incurred management fees of $13,540 to GB Capital Ltd. under a Secondment Agreement for management services for the nine months ended September 30, 2025.
• Incurred management fees of $61,260 to Northstrive Companies Inc. under a Secondment Agreement for management services for the nine months ended September 30, 2025.
• As of September 30, 2025, $315,097 was due to companies controlled by Braeden Lichti, unsecured, non-interest bearing, and due on demand.
• As of September 30, 2025, $170,498 in consulting fees was due to Graydon Bensler, unsecured, non-interest bearing, and due on demand.
• As of September 30, 2025, $1,252 was due to Jeffrey Parry for expenses incurred on behalf of the company, unsecured, non-interest bearing, and due on demand.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing capital raises (ELOC, ATM program, warrant exercises) and the impact of multiple reverse stock splits. The 'going concern' warning indicates high investment risk.
• Employees: Management changes, particularly the departure of former executives, could impact morale and operational continuity. Retention bonuses for acquired companies' employees aim to stabilize new teams.
• Customers: High customer concentration in new segments (75% from 5 key customers) means a loss of a major customer could severely impact revenue. The company's ability to maintain quality and delivery from new acquisitions is crucial.
• Suppliers: High supplier concentration (28% of costs from 2 key suppliers) creates dependency, though management believes alternatives are available in the short term.
• Creditors: The 'going concern' warning and reliance on future financing increase risk for current and potential creditors, particularly for the new convertible debt facility.

Next Steps

• Increase revenue by achieving successful returns on capital through PMGC Capital LLC's investment activities.
• Establish new wholly-owned subsidiaries to develop and commercialize newly acquired or licensed assets across various industries.
• Utilize clinical validation studies to strengthen the commercial potential and scientific credibility of portfolio companies' technologies.
• Advance clinical development to progress NorthStrive Biosciences, Inc.'s EL-22 toward Investigational New Drug (IND) applications.
• Pursue additional acquisitions of operating business-to-business companies with positive EBITDA.
• Evaluate potential opportunities such as out-licensing biotechnology applications, potential spin-offs, and creating new publicly traded companies (e.g., Special Purpose Acquisition Corporations SPACs).
• Complete the evaluation of purchase price allocation and fair value determination for the Indarg Engineering, Inc. acquisition, to be reflected in subsequent reporting periods.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, evidenced by a growing accumulated deficit of over $18 million and consistent operating losses. While the strategic shift and recent acquisitions have generated new revenue, the increased net loss and heavy reliance on continuous equity financing to sustain operations present significant financial instability and high risk for investors. The multiple reverse stock splits further underscore underlying issues, making the stock a high-risk investment with a strong likelihood of further value erosion.

Keywords

Diversified Holding Company, IT Packaging, CNC Machining, Biopharmaceutical, Medical Aesthetics, Biotechnology, Acquisitions, EL-22, GLP-1, SEC Filing, 10-Q, Financial Performance, Going Concern, Capital Raise, Reverse Stock Split